1999). Expression of the principal receptor for FGF-2, FGFR1, is also elevated in BPH, suggesting upregulation of the FGF-2 signaling pathway in BPH (Boget et al. 2001). Finasteride’s mode of action is based on the involvement of FGF-2 in BPH. BPH treated with finasteride was associated with a reduction in FGF-2 level in comparison to untreated BPH, indicating that regulation of FGF-2 in BPH is dependent, at least in part, on DHT (Sáez et al. 1999). This evidence concerns the gene FGFR1 and benign prostatic hyperplasia.